FOLFOXIRI for First-Line Treatment of Unresectable Colorectal Cancer with Liver Metastases in a Resource-Limited Setting
Journal of Gastrointestinal Cancer · 2025
DOI: 10.1007/s12029-024-01133-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastrointestinal Cancer, 2025. Verfasst von Vuong Dinh Thy Hao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chemotherapy Department, Cancer Center, Cho Ray Hospital, Ho Chi Minh City, Vietnam. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Liver Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Fluorouracil. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: FOLFOXIRI is a standard treatment for unresectable colorectal cancer (CRC) liver metastases. However, limited data exists on its safety and effectiveness in low-to-middle-income countries (LMICs). This prospective study addresses this gap in a Vietnamese LMIC setting. METHODS: We enrolled 92 patients with unresectable CRC liver metastases between 2022 and 2023. All patients received FOLFOXIRI every 2 weeks, with routine G-CSF prophylaxis to prevent neutropenia. A multidisciplinary team (MDT) assessed diagnoses and treatment responses. Outcomes were R0/R1 resection rate, progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), adverse events (AEs), and recurrence-free survival (RFS) for surgical patients. RESULTS: The median patient age was 56 years, with a male predominance (70.7%). The primary tumors were located in the left colon (42.4%), rectum (37%), and right colon (20.7%). Thirty-two patients (34.8%) experienced severe (grade 3 or higher) AEs, with thrombocytopenia (13.1%) and anemia (9.8%) being the most frequent. Most patients (72/87, 82.9%) achieved a partial response. The ORR and DCR were 85.1% and 95.4%, respectively. Fifty-seven patients (62%) achieved resectability, and 54 (58.7%) underwent radical surgery. The R0/R1 resection rate was 88.9%. The median PFS and OS for all patients were 13 and 22 months, respectively. The median RFS of surgical patients was 14 months. CONCLUSIONS: FOLFOXIRI improves the response rates, R0/R1 resection rates, and survivals for patients with CRC liver metastases. Future research is necessary to improve the prognosis of patients while minimizing toxicities. TRIAL REGISTRATION: NCT05362825 dated 5 May 2022.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chemotherapy Department, Cancer Center, Cho Ray Hospital, Ho Chi Minh City, Vietnam.
- Department of General Surgery, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
- Hepato-Pancreato-Biliary Surgery Department, Cho Ray Hospital, Ho Chi Minh City, Vietnam.
- Digestive Surgery Department, Cho Ray Hospital, Ho Chi Minh City, Vietnam.
- Gastro-Intestinal Surgery Department, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
- Department of Medical Statistics and Informatics, Faculty of Public Health, University of Medicine and Pharmacy at Ho Chi Minh City, 217 Hong Bang, Ward 11, District 5, Ho Chi Minh City, Vietnam. nguyenlamvuong@ump.edu.…
Zitieren
APA
Hao, V. D. T., Tri, P. M., My, D. T., Anh, L. T., Trung, L. V., Bac, N. H., & Vuong, N. L. (2025). FOLFOXIRI for First-Line Treatment of Unresectable Colorectal Cancer with Liver Metastases in a Resource-Limited Setting. Journal of Gastrointestinal Cancer. https://doi.org/10.1007/s12029-024-01133-4
Vancouver
Hao VDT, Tri PM, My DT, Anh LT, Trung LV, Bac NH, et al. FOLFOXIRI for First-Line Treatment of Unresectable Colorectal Cancer with Liver Metastases in a Resource-Limited Setting. Journal of Gastrointestinal Cancer. 2025. doi:10.1007/s12029-024-01133-4
BibTeX
@article{Hao2025,
author = {Hao, Vuong Dinh Thy and Tri, Phan Minh and My, Doan Tien and Anh, Le Tuan and Trung, Lam Viet and Bac, Nguyen Hoang and Vuong, Nguyen Lam},
title = {FOLFOXIRI for First-Line Treatment of Unresectable Colorectal Cancer with Liver Metastases in a Resource-Limited Setting},
journal = {Journal of Gastrointestinal Cancer},
year = {2025},
doi = {10.1007/s12029-024-01133-4}
}
EUVIMED